SYDNEY, Australia - Melbourne-based Amrad Ltd. blamed a general industry shift into late-stage research projects on the decision by GlaxoSmithKline plc and DevoCo Pharmaceuticals Ltd. to separately abandon development work on Amrad compounds. (BioWorld International)